Groundbreaking HIV Prevention Drug Shows 100% Efficacy in Phase 3 Trial 2024-06-24
A recent Phase 3 clinical trial (NCT04994509), dubbed "PURPOSE 1," has yielded promising results for a new HIV prevention drug, potentially revolutionizing the field of HIV prophylaxis. The study, conducted by Gilead Sciences, evaluated the safety and efficacy of Lenacapavir, a novel long-acting HIV
Read More